We found that ROR1Neg CLL cells that used either U or M IGHV had levels of ERK1/2 or DOCK2 that were comparable to that of ROR1Pos CLL cells (Fig. 5a). This evidence concerns the gene DOCK2 and B-cell chronic lymphocytic leukemia.